Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05258630 · ClinicalTrials.gov registry record · Phase 2
Diabetes Homeless Medication Support
A Phase 2 study of Diabetes Mellitus, Type 2 and Psychological Distress, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT05258630: Completed Phase 2 study of Diabetes Mellitus, Type 2 and Psychological Distress, sponsored by Hennepin Healthcare Research Institute.
NCT05258630 is a Phase 2 study of Diabetes Mellitus, Type 2 and Psychological Distress that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 38 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05258630, a Phase 2 study of Diabetes Mellitus, Type 2 and Psychological Distress, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized pilot trial of the Diabetes Homeless Medication Support intervention vs. brief diabetes education will test the perception and feasibility of anticipated study procedures and refine randomization and blinding.
Primary Outcome
The acceptability of the intervention to participants will be measured by the Client Satisfaction Questionnaire, 8-item version, with a score range from 8-32, higher score indicating higher satisfaction.
Conditions Studied
Interventions
- BEHAVIORAL Enhanced usual care
- BEHAVIORAL Diabetes Homeless Medication Support (D-Homes)
Study Locations (1)
Minnesota
- Hennepin Healthcare - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-02-23 |
| Est. Completion | 2023-07-12 |
| Phase | Phase 2 |
What the finished NCT05258630 record still lists
NCT05258630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Enhanced usual care is the first listed.
NCT05258630 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05258630 about?
NCT05258630 is a clinical study titled "Diabetes Homeless Medication Support". This randomized pilot trial of the Diabetes Homeless Medication Support intervention vs. brief diabetes education will test the perception and feasibility of anticipated study procedures and refine randomization and blinding.
What is the current status of trial NCT05258630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2022-02-23. Estimated completion is 2023-07-12.
What conditions does trial NCT05258630 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Psychological Distress, Housing Problems.
What interventions are being tested in trial NCT05258630?
The interventions under investigation include: Enhanced usual care (BEHAVIORAL), Diabetes Homeless Medication Support (D-Homes) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05258630?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05258630 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05258630's enrollment target sits among peer trials
38 285th of 348 higher than 64 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI